Publications

  1. Mu L, Sobotka S, Chen J, Su H, Sanders I, Adler CH, Shill HA, Caviness JN, Samanta JE, Beach TG, Arizona Parkinson's Disease Consortium. Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol. 2013 Feb; 72(2):119-29. 2297881
    View PubMed
  2. Walker DG, Lue LF, Adler CH, Shill HA, Caviness JN, Sabbagh MN, Akiyama H, Serrano GE, Sue LI, Beach TG. Changes in properties of serine 129 phosphorylated -synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol. 2013; 240(1):190-204. 2293526
  3. Lue LF, Walker DG, Adler CH, Shill H, Tran H, Akiyama H, Sue LI, Caviness J, Sabbagh MN, Beach TG. Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol. 2012 Nov; 22(6):745-56. Epub 2012 Apr 12. 2227604
    View PubMed
  4. Mu L, Sobotka S, Chen J, Su H, Sanders I, Adler CH, Shill HA, Caviness JN, Samanta JE, Beach TG, Arizona Parkinson's Disease Consortium. Altered pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol. 2012 Jun; 71(6):520-30. 2246723
    View PubMed
  5. Dugger BN, Serrano GE, Sue LI, Walker DG, Adler CH, Shill HA, Sabbagh MN, Caviness JN, Hidalgo J, Saxon-Labelle M, Chiarolanza G, Mariner M, Henry-Watson J, Beach TG, the Arizona Parkinson's Disease Consortium. Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. J Parkinsons Dis. 2012 Jan 1; 2(1):57-65. 2275075
    View PubMed
  6. Shill HA, Adler CH, Beach TG, Lue LF, Caviness JN, Sabbagh MN, Sue LI, Walker DG. Brain biochemistry in autopsied patients with essential tremor. Mov Disord. 2012 Jan; 27(1):113-7. Epub 2011 Oct 28. 2225299
    View PubMed
  7. Caviness JN. Presymptomatic Parkinson's disease: the Arizona experience. Parkinsonism Relat Disord. 2012 Jan; 18 Suppl 1:S203-6. 2213794
    View PubMed
  8. Lyons MK, Behbahani M, Boucher OK, Caviness JN, Evidente VG. Orthostatic tremor responds to bilateral thalamic deep brain stimulation. Tremor Other Hyperkinet Mov (N Y). 2012; 2. Epub 2012 Feb 20. 2306773
    View PubMed
  9. *Damian A, Adler CH, Hentz JG, Shill HA, Caviness JN, Sabbagh MN, Evidente VGH, Beach TG, Driver-Dunckley E. Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's disease. Parkinsonism Relat Disord. 2012; 18(10):1089-93. 2293282
  10. Caviness JN, Adler CH, Hentz JG, Shill HA, Evidente VG, Driver-Dunckley ED, Sabbagh MN, Sue L, Beach TG. Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disorders. Clin Neurophysiol. 2011 Dec; 122(12):2426-32. Epub 2011 May 26. 2166908
    View PubMed
  11. Evidente VG, Premkumar AP, Adler CH, Caviness JN, Driver-Dunckley E, Lyons MK. Medication dose reductions after pallidal versus subthalamic stimulation in patients with Parkinson's disease. Acta Neurol Scand. 2011 Sep; 124(3):211-4. Epub 2010 Oct 25. 2121263
    View PubMed
  12. Adler CH, Crews D, Kahol K, Santello M, Noble B, Hentz JG, Caviness JN. Are the yips a task-specific dystonia or "golfer's cramp"? Mov Disord. 2011 Sep; 26(11):1993-6. Epub 2011 Jun 14. 2169955
    View PubMed
  13. Klassen BT, Hentz JG, Shill HA, Driver-Dunckley E, Evidente VG, Sabbagh MN, Adler CH, Caviness JN. Quantitative EEG as a predictive biomarker for Parkinson disease dementia. Neurology. 2011 Jul 12; 77(2):118-24. Epub 2011 Jun 01. 2167787
    View PubMed
  14. Adler CH, Hentz JG, Shill HA, Sabbagh MN, Driver-Dunckley E, Evidente VG, Jacobson SA, Beach TG, Boeve B, Caviness JN. Probable RBD is increased in Parkinson's disease but not in essential tremor or restless legs syndrome. Parkinsonism Relat Disord. 2011 Jul; 17(6):456-8. Epub 2011 Apr 08. 2157508
    View PubMed
  15. Caviness JN, Lue LF, Beach TG, Hentz JG, Adler CH, Sue L, Sadeghi R, Driver-Dunckley E, Evidente VG, Sabbagh MN, Shill HA, Walker DG. Parkinson's disease, cortical dysfunction, and alpha-synuclein. Mov Disord. 2011 Jul; 26(8):1436-42. Epub 2011 May 03. 2163842
    View PubMed
  16. Evidente VG, Adler CH, Sabbagh MN, Connor DJ, Hentz JG, Caviness JN, Sue LI, Beach TG. Neuropathological findings of PSP in the elderly without clinical PSP: possible incidental PSP? Parkinsonism Relat Disord. 2011 Jun; 17(5):365-71. Epub 2011 Mar 21. 2155488
    View PubMed
  17. Caviness JN, Lue L, Adler CH, Walker DG. Parkinson's disease dementia and potential therapeutic strategies. CNS Neurosci Ther. 2011 Feb; 17(1):32-44. Epub 2010 Dec 28. 2141669
    View PubMed
  18. Caviness JN, Truong DD. Myoclonus. Handb Clin Neurol. 2011; 100:399-420. 2160252
    View PubMed
  19. Damian AM, Jacobson SA, Hentz JG, Belden CM, Shill HA, Sabbagh MN, Caviness JN, Adler CH. The Montreal Cognitive Assessment and the mini-mental state examination as screening instruments for cognitive impairment: item analyses and threshold scores. Dement Geriatr Cogn Disord. 2011; 31(2):126-31. Epub 2011 Jan 29. 2167017
    View PubMed
  20. Lansford KL, Liss JM, Caviness JN, Utianski RL. A cognitive-perceptual approach to conceptualizing speech intelligibility deficits and remediation practice in Hypokinetic dysarthria. Parkinson's Disease. 2011; 150962. 2211598
  21. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG, Arizona Parkinson's Disease Consortium. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010 Jun; 119(6):689-702. Epub 2010 Mar 21. 2143927
    View PubMed
  22. Adler CH, Connor DJ, Hentz JG, Sabbagh MN, Caviness JN, Shill HA, Noble B, Beach TG. Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord. 2010 Apr 15; 25(5):642-6. 1987764
    View PubMed
  23. McKinnon J, Evidente V, Driver-Dunckley E, Premkumar A, Hentz J, Shill H, Sabbagh M, Caviness J, Connor D, Adler C. Olfaction in the elderly: a cross-sectional analysis comparing Parkinson's disease with controls and other disorders. Int J Neurosci. 2010 Jan; 120(1):36-9. 1985092
    View PubMed
  24. Liss JM, White L, Mattys SL, Lansford K, Lotto AJ, Spitzer SM, Caviness JN. Quantifying speech rhythm abnormalities in the dysarthrias. J Speech Lang Hear Res. 2009 Oct; 52(5):1334-52. Epub 2009 Aug 28. 1978951
    View PubMed
  25. Driver-Dunckley E, Connor D, Hentz J, Sabbagh M, Silverberg N, Hernandez J, Vedders L, Evidente VG, Shill H, Caviness J, Adler C. No evidence for cognitive dysfunction or depression in patients with mild restless legs syndrome. Mov Disord. 2009 Sep 15; 24(12):1840-2. 1953788
    View PubMed
  26. Caviness JN. Pathophysiology and treatment of myoclonus. Neurol Clin. 2009 Aug; 27(3):757-77, vii. 1949796
    View PubMed
  27. Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, Caviness JN, Shill HA, Sue LI, Ziabreva I, Perry E, Ballard CG, Aarsland D, Walker DG, Beach TG. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):295-7. 1966675
    View PubMed
  28. Sabbagh MN, Sandhu SS, Farlow MR, Vedders L, Shill HA, Caviness JN, Connor DJ, Sue L, Adler CH, Beach TG. Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):229-33. 1966677
    View PubMed
  29. Almaraz AC, Driver-Dunckley ED, Woodruff BK, Wellik KE, Caselli RJ, Demaerschalk BM, Adler CH, Caviness JN, Wingerchuk DM. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. Neurologist. 2009 Jul; 15(4):234-7. 1952577
    View PubMed
  30. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL III, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG. Unified staging system for Lewy body disorders: Correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol (Berl). 2009 Jun; 117(6):613-34. 1982679
    View PubMed
  31. Alvarez MV, Driver-Dunckley EE, Caviness JN, Adler CH, Evidente VG. Case series of painful legs and moving toes: clinical and electrophysiologic observations. Mov Disord. 2008 Oct 30; 23(14):2062-6. 1915711
    View PubMed
  32. Alvarez M, Caviness JN. Primary progressive myoclonus of aging. Mov Disord. 2008 Sep 15; 23(12):1658-64. 1955114
    View PubMed
  33. Stamper C, Siegel A, Liang WS, Pearson JV, Stephan DA, Shill H, Connor D, Caviness JN, Sabbagh M, Beach TG, Adler CH, Dunckley T. Neuronal gene expression correlates of Parkinson's disease with dementia. Mov Disord. 2008 Aug 15; 23(11):1588-95. 1955131
    View PubMed
  34. Shill HA, Adler CH, Sabbagh MN, Connor DJ, Caviness JN, Hentz JG, Beach TG. Pathologic findings in prospectively ascertained essential tremor subjects. Neurology. 2008 Apr 15; 70(16 Pt 2):1452-5. 1909303
    View PubMed
  35. Beach TG, Adler CH, Sue LI, Peirce JB, Bachalakuri J, Dalsing-Hernandez JE, Lue LF, Caviness JN, Connor DJ, Sabbagh MN, Walker DG. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol. 2008 Apr; 115(4):445-51. Epub 2007 Nov 06. 1902589
    View PubMed
  36. Weismer G, Barlow S, Smith A, Caviness J. Special Panel Session: Driving Critical Initiatives in Motor Speech. J Med Speech Lang Pathol. 2008; 16(4):283. 2288269
    View PubMed
  37. McKinnon JH, Demaerschalk BM, Caviness JN, Wellik KE, Adler CH, Wingerchuk DM. Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders? Neurologist. 2007 Nov; 13(6):382-5. 1867416
    View PubMed
  38. Beach TG, Sue LI, Walker DG, Lue LF, Connor DJ, Caviness JN, Sabbagh MN, Adler CH. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol (Berl) 2007 Oct; 114(4):419-24. Epub 2007 Jul 17. 1844542
    View PubMed
  39. Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J, Krahn L, Adler CH. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol. 2007 Sep-Oct; 30(5):249-55. 1844480
    View PubMed
  40. Caviness JN, Hentz JG, Evidente VG, Driver-Dunckley E, Samanta J, Mahant P, Connor DJ, Sabbagh MN, Shill HA, Adler CH. Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. Parkinsonism Relat Disord. 2007 Aug; 13(6):348-54. Epub 2007 Mar 08. 1834797
    View PubMed
  41. Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH. Defining mild cognitive impairment in Parkinson's disease. Mov Disord. 2007 Jul 15; 22(9):1272-7. 1837036
    View PubMed
  42. Arvanitakis Z, Witte RJ, Dickson DW, Tsuboi Y, Uitti RJ, Slowinski J, Hutton ML, Lin SC, Boeve BF, Cheshire WP, Pooley RA, Liss JM, Caviness JN, Strongosky AJ, Wszolek ZK. Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). Parkinsonism Relat Disord. 2007 May; 13(4):230-9 Epub 2006 Dec 29. 1828150
    View PubMed
  43. Sabbagh MN, Lahti T, Connor DJ, Caviness JN, Shill H, Vedders L, Mahant P, Samanta J, Burns RS, Evidente VG, Driver-Dunckley E, Reisberg B, Bircea S, Adler CH. Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease. Dement Geriatr Cogn Disord. 2007; 24(5):327-34. Epub 2007 Sep 13. 1848862
    View PubMed
  44. Caviness JN. Parkinsonism & related disorders. Myoclonus. Parkinsonism Relat Disord. 2007; 13 Suppl 3:S375-84. 1904559
    View PubMed
  45. Langbehn DR, Paulsen JS, Hedges P, McCusker E, Pearce S, Trent R, Abwender D, Como P, Gardiner I, Hickey C, Kayson E, Kieburtz K, Marshall F, Pearson N, Shoulson I, Zimmerman C, Louis E, Marder K, Moskowitz C, Polanco C, Taylor S, Zubin N, Brown C, Predictors of diagnosis in Huntington disease. Neurology. 2007; 68(20):1710-7. 1975881
    View PubMed
  46. Liss JM, Krein-Jones K, Wszolek ZK, Caviness JN. Speech characteristics of patients with pallido-ponto-nigral degeneration and their application to presymptomatic detection in at-risk relatives. Am J Speech Lang Pathol. 2006 Aug; 15(3):226-35. 1836871
    View PubMed
  47. Hoffman Snyder C, Mishark KJ, Caviness JN, Drazkowski JF, Caselli RJ. Nonvasculitic autoimmune inflammatory meningoencephalitis imitating Creutzfeldt-Jakob disease. Arch Neurol. 2006 May; 63(5):766-8. 1765157
    View PubMed
  48. Caviness JN, Liss JM, Adler C, Evidente V. Analysis of high-frequency electroencephalographic-electromyographic coherence elicited by speech and oral nonspeech tasks in Parkinson's disease. J Speech Lang Hear Res. 2006 Apr; 49(2):424-38. 1775640
    View PubMed
  49. Caviness JN, Shill HA, Sabbagh MN, Evidente VG, Hernandez JL, Adler CH. Corticomuscular coherence is increased in the small postural tremor of Parkinson's disease. Mov Disord. 2006 Apr; 21(4):492-9. 1760748
    View PubMed
  50. Sabbagh MN, Silverberg N, Bircea S, Majeed B, Samant S, Caviness JN, Reisberg B, Adler CH. Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease? Parkinsonism Relat Disord. 2005 Aug; 11(5):311-5. 1729897
    View PubMed
  51. Tsuboi Y, Josephs KA, Boeve BF, Litvan I, Caselli RJ, Caviness JN, Uitti RJ, Bott AD, Dickson DW. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord. 2005 Aug; 20(8):982-8. 1730007
    View PubMed
  52. Caviness JN, Brown P. Myoclonus: current concepts and recent advances. Lancet Neurology. 2004 Oct; 3(10):598-607. 1665866
    View PubMed
  53. Badhwar A, Berkovic SF, Dowling JP, Gonzales M, Narayanan S, Brodtmann A, Berzen L, Caviness J, Trenkwalder C, Winkelmann J, Rivest J, Lambert M, Hernandez-Cossio O, Carpenter S, Andermann F, Andermann E. Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder. Brain. 2004 Oct; 127(Part 10):2173-82. 1665910
    View PubMed
  54. Adler CH, Bansberg SF, Hentz JG, Ramig LO, Buder EH, Witt K, Edwards BW, Krein-Jones K, Caviness JN. Botulinum toxin type A for treating voice tremor. Arch Neurol. 2004 Sep; 61(9):1416-20. 1663737
    View PubMed
  55. Adler CH, Hauser RA, Sethi K, Caviness JN, Marlor L, Anderson WM, Hentz JG. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology. 2004 Apr 27; 62(8):1405-7. 1644246
    View PubMed
  56. Caviness JN, Adler CH, Sabbagh MN, Connor DJ, Hernandez JL, Lagerlund TD. Abnormal corticomuscular coherence is associated with the small amplitude cortical myoclonus in Parkinson's disease. Mov Disord. 2003 Oct; 18(10):1157-62. 1419999
    View PubMed
  57. Evidente VG, Caviness JN, Adler CH. Case studies in movement disorders. Semin Neurol. 2003 Sep; 23(3):277-84. 1431525
    View PubMed
  58. Caviness JN, Evidente VGH. Cortical myoclonus during lithium exposure. Arch Neurol. 2003 Mar; 60(3):401-4. 1325116
    View PubMed
  59. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord. 2003 Mar; 18(3):287-93. 1325090
    View PubMed
  60. Caviness JN. Myoclonus and neurodegenerative disease - what's in a name? Parkinsonism & Related Disorders. 2003 Mar; 9(4):185-92. 1319035
    View PubMed
  61. Caviness JN, Tsuboi Y, Wszolek ZK. Clinical-electrophysiological correlation of tremor and myoclonus in a kindred with the N279K tau mutation. Parkinsonism & Related Disorders. 2003 Jan; 9(3):151-7. 1318603
    View PubMed
  62. Caviness JN. Chapter 32 The clinical neurophysiology of myoclonus. Handbook of Clinical Neurophysiology. 2003; 1(C):521-48. 2118973
  63. Adler CH, Hentz JG, Joyce JN, Beach T, Caviness JN. Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism & Related Disorders. 2002 Dec; 9(2):103-10. 1317329
    View PubMed
  64. Liss JM, Spitzer SM, Caviness JN, Adler C. The effects of familiarization on intelligibility and lexical segmentation in hypokinetic and ataxic dysarthria. J Acoust Soc Am. 2002 Dec; 112(6):3022-30. 1317751
    View PubMed
  65. Joyce JN, Ryoo HL, Beach TB, Caviness JN, Stacy M, Gurevich EV, Reiser M, Adler CH. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D-3 and not D-2 receptors. Brain Res. 2002 Nov 15; 955(1-2):138-52. 1317379
    View PubMed
  66. Caviness JN, Adler CH, Beach TG, Wetjen KL, Caselli RJ. Small-amplitude cortical myoclonus in Parkinson's disease: Physiology and clinical observations. Mov Disord. 2002 Jul; 17(4):657-62. 1315076
    View PubMed
  67. Kompoliti K, Adler CH, Raman R, Pincus JH, Leibowitz MT, Ferry JJ, Blasucci L, Caviness JN, Leurgans S, Chase WM, Yones LC, Tan E, Carvey P, Goetz CG. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22. 1315677
    View PubMed
  68. Caviness JN, Smith BE, Stevens JC, Adler CH, Caselli RJ, Hentz JG, Manfred MS, Muenter D. Motor unit number estimates in idiopathic Parkinson's disease. Parkinsonism Relat Disord. 2002 Jan; 8(3):161-4. 1008085
    View PubMed
  69. Caviness JN, Adler CH, Beach TG, Wetjen KL, Caselli RJ. Myoclonus in Lewy body disorders. Adv Neurol. 2002; 89:23-30. 1639541
    View PubMed
  70. Caviness JN. Epidemiology of myoclonus. Adv Neurol. 2002; 89:19-22. 1639542
    View PubMed
  71. Ahlskog JE, Nishino H, Evidente VG, Tulloch JW, Forbes GS, Caviness JN, Gwinn-Hardy KA. Persistent chorea triggered by hyperglycemic crisis in diabetics. Mov Disord. 2001 Sep; 16(5):890-8. 1006383
    View PubMed
  72. Evidente VG, Caviness JN, Adler CH, Gwinn-Hardy KA, Pratley RE. Serum leptin concentrations and satiety in Parkinson's disease patients with and without weight loss. Mov Disord. 2001 Sep; 16(5):924-7. 1006384
    View PubMed
  73. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, Dubinsky RM, Friedman JH, Manyam BV, Matsumoto JY, Pullman SL, Rajput AH, Sethi KD, Tanner C, Koller WC. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001 Jun 12; 56(11):1523-8. 1005198
    View PubMed
  74. Caviness JN. Primary care guide to myoclonus and chorea. Characteristics, causes and clinical options. Postgrad Med. 2000 Oct; 108(5):163-6, 169-72. 1013190
    View PubMed
  75. Cooper C, Evidente VG, Hentz JG, Adler CH, Caviness JN, Gwinn-Hardy K. The effect of temperature on hand function in patients with tremor. J Hand Ther. 2000 Oct-Dec; 13(4):276-88. 1013559
    View PubMed
  76. Liss JM, Spitzer SM, Caviness JN, Adler C, Edwards BW. Lexical boundary error analysis in hypokinetic and ataxic dysarthria. J Acoust Soc Am. 2000 Jun; 107(6):3415-24. 1012022
    View PubMed
  77. Evidente VG, Gwinn-Hardy KA, Caviness JN, Gilman S. Hereditary ataxias. Mayo Clin Proc. 2000 May; 75(5):475-90. 1013176
    View PubMed
  78. Caviness JN, Smith BE, Stevens JC, Adler CH, Caselli RJ, Reiners CA, Hentz JG, Muenter MD. Motor unit changes in sporadic idiopathic Parkinson's disease. Mov Disord. 2000 Mar; 15(2):238-43. 1012745
    View PubMed
  79. Evidente VG, Adler CH, Caviness JN, Hentz JG, Gwinn-Hardy K. Amantadine is beneficial in restless legs syndrome. Mov Disord. 2000 Mar; 15(2):324-7. 1011764
    View PubMed
  80. Gwinn-Hardy KA, Crook R, Lincoln S, Adler CH, Caviness JN, Hardy J, Farrer M. A kindred with Parkinson's disease not showing genetic linkage to established loci. Neurology. 2000 Jan 25; 54(2):504-7. 1011665
    View PubMed
  81. Pratley RE, Salbe AD, Ravussin E, Caviness JN. Higher sedentary energy expenditure in patients with Huntington's disease. Ann Neurol. 2000 Jan; 47(1):64-70. 1013164
    View PubMed
  82. Caviness JN, Gwinn-Hardy K, Adler CH, Muenter MD. Electrophysical observations in hereditary Parkinsonism-dementia with Lewy body pathology. Mov Disord. 2000 Jan; 15(1):140-145. 1014279
    View PubMed
  83. Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB, Siemers E, Shoulson I, Caviness JN, The Huntington Study Group. Rate of functional decline in Huntington’s disease. Neurology. 2000; 54:452-8. 1696394
    View PubMed
  84. Spitzer SM, Liss JM, Caviness JN, Adler CH. An exploration of familiarization effects in the perception of hypokinetic and ataxic dysarthic speech. J of Med Speech-Language Path. 2000; 8:285-93. 1727451
  85. Caviness JN, Alving LI, Maraganore DM, Black RA, McDonnell SK, Rocca WA. The incidence and prevalence of myoclonus in Olmsted County, Minnesota. Mayo Clin Proc. 1999 Jun; 74(6):565-9. 115945
    View PubMed
  86. Evidente VG, Gwinn-Hardy K, Caviness JN, Adler CH. Risperidone is effective in severe hemichorea/hemiballismus. Mov Disord. 1999 Mar; 14(2):377-9. 1701572
    View PubMed
  87. Caselli RJ, Stelmach GE, Caviness JN, Timmann D, Royer T, Boeve BF, Parisi JE. A kinematic study of progressive apraxia with and without dementia. Mov Disord. 1999 Mar; 14(2):276-87. 1009437
    View PubMed
  88. Evidente VG, Caviness JN, Jamieson B, Weaver A, Joshi N. Intersubject variability and intrasubject reproducibility of the bereitschaftspotential. Mov Disord. 1999 Mar; 14(2):313-9. 1009265
    View PubMed
  89. Evidente VG, Caviness JN. Focal cortical transient preceding myoclonus during lithium and tricyclic antidepressant therapy. Neurology. 1999 Jan 1; 52(1):211-3. 1011170
    View PubMed
  90. Evidente VG, Adler CH, Caviness JN, Gwinn-Hardy K. A pilot study on the motor effects of rimantadine in Parkinson's disease. Clin Neuropharmacol. 1999 Jan-Feb; 22(1):30-2. 1008447
    View PubMed
  91. Liss JM, Spitzer S, Caviness JN, Adler C, Edwards B. Syllabic strength and lexical boundary decisions in the perception of hypokinetic dysarthric speech. J Acoust Soc Am. 1998 Oct; 104(4):2457-66. 108018
    View PubMed
  92. Evidente VG, Adler CH, Caviness JN, Gwinn KA. Effective treatment of orthostatic tremor with gabapentin. Mov Disord. 1998 Sep; 13(5):829-31. 1019013
    View PubMed
  93. Evidente VG, Gwinn KA, Caviness JN, Hirschorn K, Deen HG. Surgically responsive focal tremor associated with a frontal convexity meningioma. Eur Neurol. 1998 Aug; 40(2):107-8. 1020462
    View PubMed
  94. Caviness JN, Adler CH, Newman S, Caselli RJ, Muenter MD. Cortical myoclonus in levodopa-responsive parkinsonism. Mov Disord. 1998 May; 13(3):540-4. 1018817
    View PubMed
  95. Evidente VG, Gwinn KA, Caviness JN, Muenter M, Mulder DW. Early cinematographic cases of postencephalitic parkinsonism and other movement disorders. Mov Disord. 1998 Jan; 13(1):167-9. 1019945
    View PubMed
  96. Caviness JN, Kurth M. Cortical Myoclonus in Huntington's disease associated with an enlarged somatosensory evoked potential. Mov Disord. 1997 Nov; 12(6):1046-51. 1017415
    View PubMed
  97. Uitti RJ, Wharen RE Jr, Turk MF, Lucas JA, Finton MJ, Graff-Radford NR, Boylan KB, Goerss SJ, Kall BA, Adler CH, Caviness JN, Atkinson EJ. Unilateral pallidotomy for Parkinson's disease: comparison of outcome in younger versus elderly patients. Neurology. 1997 Oct; 49(4):1072-7. 1314295
    View PubMed
  98. Adler CH, Caviness JN. Dystonia secondary to electrical injury: surface electromyographic evaluation and implications for the organicity of the condition. J Neurol Sci. 1997 May 29; 148(2):187-92. 1015940
    View PubMed
  99. Gwinn KA, Caviness JN. Electrophysiological observations in idiopathic opsoclonus-myoclonus syndrome. Mov Disord. 1997 May; 12(3):438-42. 1017618
    View PubMed
  100. Kurth MC, Adler CH, Sthilaire M, Singer C, Waters C, Lewitt P, Chernik DA, Dorflinger EE, Yoo K, Lieberman AN, Brewer M, Sainthilaire M, Pery LM, Thomas C, Turpin L, Obrien CF, Seeberger LC, Duncan KL, Caviness JN, Douglas M, Wheeler K, Riley D, Rainey P, Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations - a multicenter, double blind, randomized, placebo-controlled trial. Neurology. 1997 Jan; 48(1):81-87. 1314263
    View PubMed
  101. Gwinn KA, Caviness JN. Risperidone-induced tardive dyskinesia and parkinsonism. Mov Disord. 1997 Jan; 12(1):119-21. 1017507
    View PubMed
  102. Lieberman A, Caviness JN, The Pramipexole Study Group. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controled, parallel-group study. Neurology. 1997; 49(162-8). 1727781
  103. Weber JG, Cunnien AJ, Hinni ML, Caviness JN. Psychogenic coma after use of general anesthesia for ethmoidectomy. Mayo Clin Proc. 1996 Aug; 71(8):797-800. 1027183
    View PubMed
  104. Caviness JN. Myoclonus. Mayo Clin Proc. 1996 Jul; 71(7):679-88. 1027110
    View PubMed
  105. Caviness JN, Forsyth PA, Layton DD, McPhee TJ. The movement disorder of adult opsoclonus. Mov Disord. 1995 Jan; 10(1):22-7. 1023267
    View PubMed
  106. Matsumoto JY, Caviness JN, McEvoy KM. The acoustic startle reflex in stiff-man syndrome. Neurology. 1994 Oct; 44(10):1952-5. 1033290
    View PubMed
  107. Muenter MD, Daube JR, Caviness JN, Miller PM. Treatment of essential tremor with methazolamide. Mayo Clin Proc. 1991 Oct; 66(10):991-7. 1038235
    View PubMed
  108. Caviness JN, Muenter MD. An unusual cause of recurrent chorea. Mov Disord. 1991; 6(4):355-7. 1038389
    View PubMed
  109. Caviness JN, Wightman RM. Use of rapid superfusion to differentiate the release of dopamine from striatal tissue induced by sympathomimetic amines from release induced by potassium. Journal of Pharmacology & Experimental Therapeutics. 1982 Oct; 223(1):90-6. 1115228
    View PubMed
  110. Wightman RM, Bright CE, Caviness JN. Direct measurement of the effect of potassium, calcium, veratridine, and amphetamine on the rate of release of dopamine from superfused brain tissue. Life Sci. 1981 Mar 16; 28(11):1279-86. 1112651
    View PubMed